PROSTAGLANDIN D2 RECEPTOR 2

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 12:39:02 UTC 2023` Edited by `admin` on `Sat Dec 16 12:39:02 UTC 2023`
Protein Type	RECEPTOR
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	X4HG9CCA5A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROSTAGLANDIN D2 RECEPTOR 2

Common Name

English

CD_ANTIGEN: CD294

Common Name

English

PROSTANOID DP2 RECEPTOR

Common Name

English

CRTH2

Common Name

English

DP2

Common Name

English

GPR44

Common Name

English

CHEMOATTRACTANT RECEPTOR-HOMOLOGOUS MOLECULE EXPRESSED ON TH2 CELLS

Common Name

English

D PROSTANOID RECEPTOR 2

Common Name

English

G-PROTEIN COUPLED RECEPTOR 44

Common Name

English

DL1R

Common Name

English

Code System Code Type Description

UNIPROT

Q9Y5Y4

Created by admin on Sat Dec 16 12:39:02 UTC 2023 , Edited by admin on Sat Dec 16 12:39:02 UTC 2023

PRIMARY

FDA UNII

X4HG9CCA5A

Created by admin on Sat Dec 16 12:39:02 UTC 2023 , Edited by admin on Sat Dec 16 12:39:02 UTC 2023

PRIMARY

PHAROS

Q9Y5Y4

Created by admin on Sat Dec 16 12:39:02 UTC 2023 , Edited by admin on Sat Dec 16 12:39:02 UTC 2023

PRIMARY

WIKIPEDIA

Prostaglandin DP2 receptor

Created by admin on Sat Dec 16 12:39:02 UTC 2023 , Edited by admin on Sat Dec 16 12:39:02 UTC 2023

PRIMARY

From	To
1_104	1_182

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_4
N	1_25

Related Record Type Details


					TN6MJ43BDM

AM-432

INHIBITOR -> TARGET

Amount:


					61OTZ32XNC

VIDUPIPRANT

INHIBITOR -> TARGET

Amount:


					P1ALI72U6C

RAMATROBAN

INHIBITOR -> TARGET

Amount:


					Y44QME68PZ

TM-30643

INHIBITOR -> TARGET

Amount:


					5LO1ZK1LCW

ARRY-502

INHIBITOR -> TARGET

Amount:


					04XB9TB8OL

TIMAPIPRANT

INHIBITOR -> TARGET

Comments:

A post hoc analysis revealed that the greatest improvement of lung function by timapiprant was observed in patients with active eosinophilia (≥250/μl peripheral blood) and—even more pronounced—in younger patients (90). This applies also for the humanized murine IL-5 antibody mepolizumab, which is most effective and only given in asthma patients with severe eosinophilic airway inflammation (91). In eosinophil esophagitis, timapiprant significantly reduced the esophageal eosinophil load and induced some clinical improvement (92). Timapiprant also successfully reduced nasal and ocular symptoms in allergic subjects exposed to grass pollen (93).

Amount: